Long-term Control of Cystoid Macular Oedema in Noninfectious Uveitis with Mycophenolate Mofetil

Overview

Journal Int Ophthalmol

Specialty Ophthalmology

Date 2008 Feb 26

PMID 18297240

Citations 15

Authors

Piergiorgio Neri

Cesare Mariotti

Luca Cimino

Lucia Mercanti

Alfonso Giovannini

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the long-term safety and efficacy of Mycophenolate Mofetil (MMF) for the control of cystoid macular oedema (CMO) secondary to noninfectious uveitis (NU).

Methods: The medical records of 19 consecutive patients with inflammatory CMO treated with MMF were retrospectively reviewed. Patient demographics, best corrected visual acuity (BCVA), fluorescein angiography (FA), and optical coherence tomography (OCT) findings were evaluated.

Results: There were eight females and 11 males with a mean age of 32.9 +/- 8.9 years. After a 1-year follow-up, 18/19 patients (31 eyes, 96.9%, P < 0.05) no longer had signs of CMO, as per their FA and OCT findings; the mean central foveal thickness (CFT) was 167.2 +/- 12.8 microm. At the last follow-up, only 3/19 patients, all affected by Behçet panuveitis, had recurrences of CMO. Mean BCVA improved from 0.34 +/- 0.14 SD at baseline to 0.65 +/- 0.2 SD at last follow-up.

Conclusions: MMF was safe and effective in controlling CMO and in reducing the uveitis relapse rate in patients not responding to traditional immunosuppressants. Further case-controlled studies are mandatory to validate those preliminary results.

Citing Articles

Bromfenac 0.09% for the Treatment of Macular Edema Secondary to Noninfectious Uveitis.

S Saade J, Istambouli R, Abdulaal M, Antonios R, Hamam R Middle East Afr J Ophthalmol. 2021; 28(2):98-103.

PMID: 34759667 PMC: 8547661. DOI: 10.4103/meajo.meajo_134_21.

Intraocular Inflammation Control and Changes in Retinal and Choroidal Architecture in Refractory Non-Infectious Uveitis Patients after Adalimumab Therapy.

Pirani V, Pelliccioni P, De Turris S, Rosati A, Franceschi A, Pasanisi P J Clin Med. 2020; 9(2).

PMID: 32069898 PMC: 7074084. DOI: 10.3390/jcm9020510.

Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges.

Massa H, Pipis S, Adewoyin T, Vergados A, Patra S, Panos G Clin Ophthalmol. 2019; 13:1761-1777.

PMID: 31571815 PMC: 6750710. DOI: 10.2147/OPTH.S180580.

Orbital Vasculitides-Differential Diagnosis.

Espinoza G, Liu J Curr Rheumatol Rep. 2019; 21(10):54.

PMID: 31486966 DOI: 10.1007/s11926-019-0853-6.

Update in treatment of uveitic macular edema.

Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos P Drug Des Devel Ther. 2019; 13:667-680.

PMID: 30858697 PMC: 6387597. DOI: 10.2147/DDDT.S166092.

References

. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation. 1996; 61(7):1029-37. View

Vinores S, Chan C, Vinores M, Matteson D, Chen Y, Klein D . Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998; 89(1-2):43-50. DOI: 10.1016/s0165-5728(98)00075-7. View

SPATZ S, Rudnicka A, McDonald C . Mycophenolic acid in psoriasis. Br J Dermatol. 1978; 98(4):429-35. DOI: 10.1111/j.1365-2133.1978.tb06537.x. View

Kilmartin D, Forrester J, Dick A . Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998; 352(9121):35-6. DOI: 10.1016/S0140-6736(05)79515-5. View

Neri P, Azuara-Blanco A, Forrester J . Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004; 13(6):461-5. DOI: 10.1097/01.ijg.0000146391.77618.d0. View

Thorne J, Jabs D, Qazi F, Nguyen Q, Kempen J, Dunn J . Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005; 112(8):1472-7. DOI: 10.1016/j.ophtha.2005.02.020. View

Kilmartin D, Forrester J, Dick A . Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm. 1998; 6(2):101-9. DOI: 10.1076/ocii.6.2.101.4051. View

Deuter C, Koetter I, Guenaydin I, Stuebiger N, Zierhut M . Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006; 26(7):786-91. DOI: 10.1097/01.iae.0000244265.75771.71. View

Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M . Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2006; 91(2):180-4. PMC: 1857605. DOI: 10.1136/bjo.2006.094698. View

10.

. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet. 1995; 345(8961):1321-5. View

11.

Bom S, Zamiri P, Lightman S . Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2001; 9(1):35-40. DOI: 10.1076/ocii.9.1.35.3983. View

12.

Jabs D, Nussenblatt R, Rosenbaum J . Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005; 140(3):509-16. PMC: 8935739. DOI: 10.1016/j.ajo.2005.03.057. View

13.

Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A . Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol. 2005; 140(2):200-6. DOI: 10.1016/j.ajo.2005.02.053. View

14.

Dick A . Are we still reluctant to immunosuppress?. Clin Exp Ophthalmol. 2005; 33(1):1-2. DOI: 10.1111/j.1442-9071.2004.00935.x. View

15.

Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M . Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2005; 244(7):788-94. DOI: 10.1007/s00417-005-0066-8. View

16.

Greenwood A, Stanford M, Graham E . The role of azathioprine in the management of retinal vasculitis. Eye (Lond). 1999; 12 ( Pt 5):783-8. DOI: 10.1038/eye.1998.203. View

17.

Jabs D, Rosenbaum J, Foster C, Holland G, Jaffe G, Louie J . Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000; 130(4):492-513. DOI: 10.1016/s0002-9394(00)00659-0. View

18.

Nussenblatt R . Macular alterations secondary to intraocular inflammatory disease. Ophthalmology. 1986; 93(7):984-8. DOI: 10.1016/s0161-6420(86)33654-6. View

19.

Lau C, Comer M, Lightman S . Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003; 31(6):487-91. DOI: 10.1046/j.1442-9071.2003.00704.x. View

20.

Sollinger H . Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation. 1995; 60(3):225-32. DOI: 10.1097/00007890-199508000-00003. View